TCRX — Tscan Therapeutics Share News
0.000.00%
Last trade - 00:00- $13.21m
- -$54.17m
- $10.33m
U.S. STOCKS ON THE MOVE-FuelCell, Gold miners, NetApp
U.S. STOCKS ON THE MOVE-AEVEX, Sirius XM, PG&E
U.S. STOCKS ON THE MOVE-TScan Therapeutics, EOS Energy, Brown-Forman Corp
Brief: TScan Therapeutics - Amgen To Terminate Research Collaboration And License Agreement With TScan Therapeutics - SEC Filing
TScan Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
TScan Therapeutics Q2 net loss narrows on lower R&D costs
Brief: TScan Therapeutics Q2 Net Income USD -30.359 Million
TScan Therapeutics Inc expected to post a loss of 21 cents a share - Earnings Preview
Brief: Tscan Therapeutics Announces Positive Initial Data From Phase 1 Study In Patients With Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
TScan Therapeutics Q4 net loss widens
Brief: Tscan Therapeutics Completes Enrollment In Cohort C Of Phase 1 Alloha™ Trial
TScan Therapeutics Q3 revenue jumps
Brief: TScan Therapeutics Q3 Net Income USD -35.71 Million
Brief: TScan Therapeutics Announces 30% Workforce Reduction, Cash Runway Extension
Brief: TScan Therapeutics Expects $2.3 Million One-Time Charge For Severance During 3 Months Ended Dec 31
TScan Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
TScan Therapeutics Inc expected to post a loss of 28 cents a share - Earnings Preview
Brief: TScan Therapeutics Inc Files For Mixed Shelf Of Up To $300 Million
Brief: TScan Therapeutics Q3 Net Income USD -29.887 Million